Free tool
FAERS Monitor: Egaten
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208711 or its brand name (Egaten, Triclabendazole). Reports on generic versions are filed under their own applications.
Reports
44
Serious
24
55% of reports
Hospitalization
5
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malaise7
- trematode infection5
- fascioliasis4
- condition aggravated3
- illness3
- nausea3
- overdose3
- rash3
- abdominal pain2
- chest pain2
- cough2
- diarrhoea2
- drug ineffective2
- fatigue2
- fracture2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 9 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 6 |
| 2025 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,115 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| trematode infectionSignal | 5 | 159500.9 | 60582.2 | 484,477 |
| fascioliasisSignal | 4 | 119625.7 | 41649.5 | 293,077 |
| fracture | 2 | 50.5 | 13.0 | 54 |
| illnessSignal | 3 | 13.9 | 4.7 | 24 |
| malaiseSignal | 7 | 7.6 | 3.9 | 35 |
| overdoseSignal | 3 | 6.6 | 2.2 | 9 |
| chest pain | 2 | 5.2 | 1.3 | 3 |
| condition aggravatedSignal | 3 | 4.7 | 1.6 | 6 |
| abdominal pain | 2 | 4.1 | 1.1 | 2 |
| cough | 2 | 3.4 | 0.9 | 1 |
| rash | 3 | 3.3 | 1.1 | 3 |
| nausea | 3 | 1.8 | 0.6 | 0 |
| diarrhoea | 2 | 1.5 | 0.4 | 0 |
| fatigue | 2 | 1.2 | 0.3 | 0 |
| drug ineffective | 2 | 0.7 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.